The atypical cannabinoid O-1602 increases hind paw sensitisation in the chronic constriction injury model of neuropathic pain.
O-1602 is an atypical cannabinoid that acts as an agonist at GPR55, a g protein-coupled receptor that previous studies have indicated may have a pronociceptive role in neuropathic pain. We administered O-1602 to both naive rats and rats that had undergone chronic constriction injury surgery. O-1602 did not cause any changes in hind paw responses to Von Frey hair testing in naive rats. However, O-1602 reversed the desensitising effects of ETOH, which was used as an active and opposing vehicle. Our results are consistent with the hypothesis that GPR55 has a pronociceptive role in neuropathic pain.
Department of Pharmacology & Toxicology, Otago School of Medical Sciences, University of Otago, PO Box 913, Dunedin 9054, New Zealand.
Courtney
C
Breen
Philip W
PW
Brownjohn
John C
JC
Ashton
D000818:Animals; D002185:Cannabidiol / Q000031:analogs & derivatives; D002186:Cannabinoids / Q000633:toxicity*; D003250:Constriction; D003510:Cyclohexanes / Q000633:toxicity*; D006614:Hindlimb; D006930:Hyperalgesia / Q000209:etiology; D008297:Male; D023421:Models, Animal; D009437:Neuralgia / Q000209:etiology*; D051381:Rats; D017208:Rats, Wistar; D012118:Resorcinols / Q000633:toxicity*
D002186:Cannabinoids; D003510:Cyclohexanes; D012118:Resorcinols; D002185:Cannabidiol; C568537:O-1602 compound